轻微型肝性脑病治疗方案的比较疗效:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入25项随机对照试验共1563例肝硬化患者,评估轻微型肝性脑病(HE)的治疗及预防显性HE的效果。结果显示利福昔明和乳果糖在逆转轻微型HE方面最有效,L-鸟氨酸L-天冬氨酸和乳果糖在预防显性HE方面最有效,乳果糖是唯一在逆转轻微型HE、预防显性HE、降低血氨及改善生活质量方面均有效的药物。
要点
- 利福昔明和乳果糖逆转轻微型HE最有效,证据质量中等。
- L-鸟氨酸L-天冬氨酸和乳果糖预防显性HE最有效。
- 乳果糖是唯一在多项结局(逆转、预防、降氨、生活质量)均有效的药物。
核心结论
- 利福昔明和乳果糖在逆转肝硬化患者轻微型HE方面最有效。
- L-鸟氨酸L-天冬氨酸和乳果糖在预防显性HE方面最有效。
- 乳果糖是唯一在逆转轻微型HE、预防显性HE、降低血氨及改善生活质量方面均有效且不良反应可耐受的药物。
研究设计与样本
- 系统检索PubMed、EMBASE、OvidSP和Cochrane CENTRAL数据库至2018年7月26日,纳入评估肝硬化患者轻微型HE治疗的随机对照试验。
- 共纳入25项试验,合计1563例参与者。
- 采用Meta分析及网状Meta分析,使用累积排序曲线下面积(SUCRA)对直接和间接估计进行合并并排序,采用GRADE系统评价研究质量。
主要发现
- 与安慰剂或无治疗相比,逆转轻微型HE有效的药物包括:利福昔明(OR 7.53,95% PrI 4.45-12.73,SUCRA 89.2%,中等质量)、乳果糖(OR 5.39,95% PrI 3.60-8.0,SUCRA 67.2%,中等质量)、益生菌联合乳果糖(OR 4.66,95% PrI 1.90-11.39,SUCRA 52.4%,低质量)、L-鸟氨酸L-天冬氨酸(OR 4.45,95% PrI 2.67-7.42,SUCRA 47.2%,低至中等质量)、益生菌(OR 3.89,95% PrI 2.52-6.02,SUCRA 34.1%,低质量)。
- 与安慰剂或无治疗相比,预防显性HE有效的药物包括:L-鸟氨酸L-天冬氨酸(OR 0.19,95% PrI 0.04-0.91,SUCRA 75.1%,高至中等质量)、乳果糖(OR 0.22,95% PrI 0.09-0.52,SUCRA 73.9%,中等质量)、益生菌(OR 0.27,95% PrI 0.11-0.62,SUCRA 59.6%,低质量)。
关键数值与推荐
- 逆转轻微型HE:利福昔明OR 7.53(95% PrI 4.45-12.73),SUCRA 89.2%,中等质量。
- 逆转轻微型HE:乳果糖OR 5.39(95% PrI 3.60-8.0),SUCRA 67.2%,中等质量。
- 预防显性HE:L-鸟氨酸L-天冬氨酸OR 0.19(95% PrI 0.04-0.91),SUCRA 75.1%,高至中等质量。
- 预防显性HE:乳果糖OR 0.22(95% PrI 0.09-0.52),SUCRA 73.9%,中等质量。
临床怎么用
- 对于肝硬化合并轻微型HE患者,可优先考虑利福昔明或乳果糖以逆转轻微型HE。
- 为预防显性HE,可选用L-鸟氨酸L-天冬氨酸或乳果糖。
- 乳果糖因在多项结局(逆转轻微型HE、预防显性HE、降低血氨、改善生活质量)均有效且耐受性可,可作为综合管理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We aimed to synthesize evidence for most effective treatments for minimal hepatic encephalopathy (HE) and prevention of overt HE in patients with cirrhosis. METHODS: We performed a systematic search of the PubMed, EMBASE, OvidSP, and Cochrane Central Register of Controlled Trials databases through July 26, 2018, for randomized controlled trials evaluating treatments for minimal HE in patients with cirrhosis, with primary outcomes of reversal of minimal HE or prevention of overt HE. We conducted a meta-analysis and then used network meta-analysis and surface under cumulated ranking (SUCRA) to pool the direct and indirect estimates and rank the different treatments. We appraised study quality using the Grading of Recommendations Assessment, Development and Evaluation system. RESULTS: Our meta-analysis and network meta-analysis included 25 trials, comprising 1563 participants. Agents found to be effective in reversing minimal HE compared with placebo or no treatment included rifaximin (odds ratio [OR], 7.53; 95% predictive interval [PrI], 4.45-12.73; SUCRA, 89.2%; moderate quality), lactulose (OR, 5.39; 95% PrI, 3.60-8.0; SUCRA, 67.2%; moderate quality), the combination of probiotics and lactulose (OR, 4.66; 95% PrI, 1.90-11.39; SUCRA, 52.4%; low quality), L-ornithine L-aspartate (OR, 4.45; 95% PrI, 2.67-7.42; SUCRA, 47.2%; low moderate quality), and probiotics (OR, 3.89; 95% PrI, 2.52-6.02; SUCRA, 34.1%; low quality). Agents found to be effective in preventing episodes of overt HE compared with placebo or no treatment included L-ornithine L-aspartate (OR, 0.19; 95% PrI, 0.04-0.91; SUCRA, 75.1%; high moderate quality), lactulose (OR, 0.22; 95% PrI, 0.09-0.52; SUCRA, 73.9%; moderate quality), and probiotics (OR, 0.27; 95% PrI, 0.11-0.62; SUCRA, 59.6%; low quality). CONCLUSIONS: In a meta-analysis of data from 25 trials, we found rifaximin and lactulose to be most effective for reversal of minimal HE in patients with cirrhosis. L-ornithine L-aspartate and lactulose are most effective in the prevention of overt HE. Lactulose was the only agent that was effective in reversing minimal HE, preventing overt HE, reducing ammonia, and improving quality of life, with tolerable adverse effects. International prospective register of systematic reviews ID: 107003.
引用
- Dhiman RK, Thumburu KK, Verma N, et al. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. Clin Gastroenterol Hepatol. 2019. PMID: 31476436. doi:10.1016/j.cgh.2019.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。